Navigation Links
Experimental Drug Eases Symptoms of Mild Alzheimer's
Date:4/30/2008

Tarenflurbil lessened decline in functional ability, British study concludes

WEDNESDAY, April 30 (HealthDay News) -- Patients with mild Alzheimer's disease who took 800 milligrams of the drug tarenflurbil twice a day had less decline in functional ability than those who took a placebo, according to a British phase II trial.

The findings support phase III studies of the drug at this dose, the researchers said. Tarenflurbil reduces production of 42-amino-acid peptide, which is believed to initiate brain damage characteristic of Alzheimer's disease. Previous research had found the drug prevented learning and memory defects in mice with Alzheimer's disease.

In this study, 210 patients were randomly assigned to receive either 400 milligrams of tarenflurbil twice per day (69 patients), 800 milligrams of tarenflurbil twice per day (70 patients), or a placebo (71 patients).

Patients with mild Alzheimer's who took 800 milligrams of tarenflurbil for 24 months had lower rates of decline than those who were in the placebo group for the first 12 months of the study and either tarenflurbil group for the last 12 months of the study.

Common side effects included diarrhea, nausea and dizziness.

The researchers concluded that "800 mg tarenflurbil twice per day was well-tolerated for up to 24 months of treatment, with evidence of a dose-related effect on measures of daily activities and global function in patients with mild AD ... these findings justify phase III studies of tarenfurbil at the 800 mg twice daily dose in patients with mild AD."

The study was published online in The Lancet Neurology.

The findings are sufficient to support Phase III studies of the drug, Dr. Paul Aisen of the University of California, San Diego, wrote in an accompanying commentary.

"With the need so enormous, and the potential effect of the benefit suggested [although not proven] by these phase II results, the effort is indeed justified despite the substantial uncertainty. In a few months, we will learn whether tarenflurbil will be the first anti-amyloid intervention to be efficacious in a pivotal trial," Aisen wrote.

More information

The U.S. National Institute on Aging has more about Alzheimer's disease.



-- Robert Preidt



SOURCE: The Lancet, news release, April 29, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Experimental Blood Substitutes Unsafe, Study Finds
2. Honda to Showcase Experimental Walking Assist Device
3. Experimental Alzheimers Drug Shows Promise
4. Experimental drug shows promise in treating certain lymphomas
5. Experimental Cancer Vaccines Show Promise
6. Gourmetceuticals Presents Findings on Science You Can Eat at Experimental Biology 2008
7. Cavities in Children Reduced Over 60 Percent by New Experimental Chewable Mints
8. Gourmetceuticals to Present Data from Four Studies at Experimental Biology 2008
9. 52 minority scientists receive travel fellowships to Experimental Biology 2008
10. Experimental Biology 2008 Todays Research: Tomorrows Health, April 5-9
11. Experimental Vaccine Halts Prostate Cancer in Mice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... The ... the Undersea and Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric medicine. ... safety. Only a few hospitals and facilities have earned this distinction. This is ...
(Date:12/8/2016)... ... 2016 , ... ZyDoc , a New York-based medical ... Capture Methods for Input to Electronic Health Records: A Comparative Usability Study” has ... usability study demonstrate that a dictation-based method (“NLP Entry”) using ZyDoc’s MediSapien™ natural ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the ... advocacy groups, has aligned with Upstage Lung Cancer in efforts to combat lung cancer, ... Michael J. Hennessy, Jr said, “CURE Media Group is honored to team up with ...
(Date:12/8/2016)... ... ... Premier Fitness Camp (PFC) and The Chopra Center for Wellbeing announced today ... at their world headquarters of Omni La Costa Resort & Spa in San Diego. ... weight loss, personal development, a healthy lifestyle, or mental and physical healing. The week-long ...
(Date:12/8/2016)... N.J. (PRWEB) , ... December 08, 2016 , ... ... delivery technologies and development solutions for drugs, biologics and consumer health products, today ... PSCI was set up in 2006 as a non-profit organization to unite pharmaceutical ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 2016  The global biosurgery market is expected to ... period of 2016 to 2021. The market is poised ... 18.21 billion in 2016. The market is primarily driven ... related injuries and spinal problems, increasing clearance of biosurgery ... blood loss management. In this report, the ...
(Date:12/8/2016)... KEY FINDINGS The global medical ... Various reasons for growth of the medical lifting sling ... chronic diseases, high recovery cost of injuries and government ... lifting sling refers to an assistive device that helps ... connect to the lift and hold the patient. It ...
(Date:12/8/2016)... Pharmacy, Inc. (NYSE: DPLO) has been recognized by the Detroit ... Standard. To learn more about Diplomat,s career opportunities, visit ... ... ... LLC, a research firm specializing in organizational health and workplace improvement. ...
Breaking Medicine Technology: